Anti-ZEB1 Antibody

ZEB1, initially identified as the delta-crystallin enhancer binding protein delta EF1, is a DNA-binding protein that binds to a modified E-box sequence and has been implicated in postgastrulation embryogenesis. ZEB1 binds to the promoter of several hemapoietic genes, including interleukin-2, CD4, GATA-3, and alpha-integrin, and mice in which ZEB1 has been targeted show thymic atrophy, and severe defects in lymphocyte differentiation. Recent evidence suggests that ZEB1 also regulates the accumulation of adipose tissue and may play a role in obesity. Mutations in this gene have been associated with late-onset Fuchs endothelial corneal dystrophy.

ZEB1 antibody was raised against a 15 amino acid synthetic peptide near the center of human ZEB1. The immunogen is located within amino acids 530 - 580 of ZEB1.

Colocalizes with SMARCA4/BRG1 in E-cadherin- negative cells from established lines, and stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas (at protein level) . Expressed in heart and skeletal muscle, but not in liver, spleen, or pancreas.

Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type. Represses E-cadherin promoter and induces an epithelial-mesenchymal transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6 transcription in the presence of the corepressor CTBP1. Positively regulates neuronal differentiation. Represses RCOR1 transcription activation during neurogenesis. Represses transcription by binding to the E box (5'-CANNTG-3') . Promotes tumorigenicity by repressing stemness-inhibiting microRNAs.